XBiotech Inc. (XBIT) Hit 12-Month High at $6.43 on Jan, 28

XBiotech Inc. (NASDAQ:XBIT) Corporate Logo

A one-year high was touched by XBiotech Inc. (NASDAQ:XBIT). Today’s price per share was $6.43. It’s 5.00 % above our $6.75. On Jan, 28 the one-year high was published by Barchart.com. The company has $230.32 million market cap. $11.52 million more could be NASDAQ:XBIT valuation at $6.75 share price.

Ticker’s shares touched $6.43 during the last trading session after 5.93% change.XBiotech Inc. has 229,139 shares volume, 167.59% up from normal. XBIT is downtrending and has moved 7.38% since January 28, 2018. XBIT underperformed the S&P500 by 7.38%.

For more XBiotech Inc. (NASDAQ:XBIT) news published recently go to: Globenewswire.com, Seekingalpha.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “XBiotech Announces New Patents for Third Quarter 2018 – GlobeNewswire” published on October 26, 2018, “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” on January 23, 2019, “XBiotech’s bermekimab shows positive effect dermatitis pilot study; shares up 28% premarket – Seeking Alpha” with a publish date: September 13, 2018, “XBiotech Announces Granting of European Patent for Treatment of Inflammatory Skin Diseases – GlobeNewswire” and the last “XBiotech Announces Dismissal of Securities Class Action Suit – GlobeNewswire” with publication date: October 24, 2018.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases.The firm is worth $230.32 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.Currently it has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *